Has durvalumab (durvalumab) been reimbursed by medical insurance? What are the proportions and conditions of medical insurance reimbursement?

Durvalumab (durvalumab) is an immune checkpoint inhibitor mainly used to treat malignant tumors such as non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC). The drug is already on the market in China, but so far it has not been included in the national medical insurance list, so patients need to purchase it at their own expense. In the domestic market, common specifications include 120mg/2.4mL and 500mg/10mL. The price per box may range from 4,000 to more than 10,000 yuan, and the specific cost varies depending on the specifications.

Since durvalumab is not covered by medical insurance, patients need to bear higher treatment costs when using this drug. However, some commercial insurance or patient assistance programs may provide a certain degree of cost reduction or subsidy. Patients can consult their doctors or relevant institutions to find out whether they meet the application conditions. In addition, some hospitals or charities may launch drug assistance programs targeted at specific patient groups to reduce the financial burden on patients.

Compared with the domestic market, the price of durvalumab in overseas markets is relatively low. For example, in the United States and Europe, the price of the drug may be more than one thousand US dollars per box. However, if patients consider obtaining the drug through overseas drug purchase channels, they need to ensure that the purchase channel is formal and comply with relevant laws and regulations on imported drugs. There are currently no generic drugs of durvalumab on the market, so patients need to be wary of counterfeit drugs or drugs from irregular sources when purchasing drugs.

In the future, if durvalumab is included in medical insurance, the financial burden on patients may be significantly reduced. The proportion and specific conditions of medical insurance reimbursement will be determined by national medical insurance policies. Usually, after cancer immunotherapy drugs are included in medical insurance, certain indications and patient conditions may be set. For example, they must meet the tumor type at a specific stage, or they must fail first-line treatment before they can be used. Patients can pay attention to the adjustment of the national medical insurance catalog, or consult the local medical insurance agency to obtain the latest reimbursement policy information.